Mutations in the gyrA gene in Salmonella enterica clinical isolates with decreased ciprofloxacin susceptibility

International Journal of Antimicrobial Agents

Volumn 24, Issue 3, 2004, Pages 300-303

  Escribano, Isabel ^a   Rodríguez, Juan C ^a   Royo, Gloria ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

Ciprofloxacin; gyrA; Nalidixic acid; Resistance; Salmonella

Indexed keywords

CIPROFLOXACIN; NALIDIXIC ACID; BACTERIAL PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING);

ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG SPECIFICITY; GENE MUTATION; GENETIC STRAIN; NONHUMAN; PRIORITY JOURNAL; SALMONELLA ENTERICA; SEROTYPE; SPAIN; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; CLASSIFICATION; DRUG EFFECT; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MISSENSE MUTATION; PHYSIOLOGY; UNIVERSITY HOSPITAL;

AMINO ACID SUBSTITUTION; BACTERIAL PROTEINS; CIPROFLOXACIN; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; HOSPITALS, UNIVERSITY; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; NALIDIXIC ACID; SALMONELLA ENTERICA; SPAIN;

EID: 4344597642     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2004.02.029     Document Type: Article

References (34)

1. Reid T.M.S. The treatment of non-typhi salmonellosis. J. Antimicrob. Chemother. 29:1992;4-8
2. Shah P.M. Use of quinolones for the treatment of patients with bacteraemia. Rev. Infect. Dis. 11(Suppl. 5):1989;1156-1159
3. Barnass S., Francklin J., Tabaqchali S. The successful treatment of multiresistant non-enteric salmonellosis with seven-day oral ciprofloxacin. J. Antimicrob. Chemother. 25:1990;299-300
4. Reina F., Gomez J., Serra A., Borell N. Analysis of the antibiotic resistance detected in 2043 strains of Salmonella enterica subsp. enterica isolated in stool cultures of Spanish patients with acute diarrhoea (1986-1991). J. Antimicrob. Chemother. 32:1993;765-769
5. Vasallo F.J., Martín-Rabadán P., Alcalá L., García-Lechuz J.M., Rodríguez-Creixems M., Bouza E. Failure of ciprofloxacin therapy for invasive non-typhoidal salmonellosis (letter). Clin. Infect. Dis. 26:1998;535-536
6. Pers C., Sogaard P., Pallesen L. Selection of multiple resistances in Salmonella enteritidis during treatment with ciprofloxacin. Scand. J. Infect. Dis. 28:1996;529-531
7. Piddock L.J.V., Whale K., Wise R. Quinolone resistance in salmonella: clinical experience (letter). Lancet. 335:1990;1459
8. Hakanen A., Kotilainen P., Jalava J., Siitonen A., Huovinen P. Detection of decreased fluoroquinolone susceptibility in salmonellas and validation of nalidixic acid screening test. J. Clin. Microbiol. 37:1999;3572-3577
9. Seral C., López L., Castillo F.J., Clavel A., Rubio M.C. Resistencia a quinolones en Salmonella enterica. Rev. Esp. Quimioter. 11:1998;43-46
10. Sirvent E., Ruíz M., Rodríguez J.C., Royo G. Serotipos y sensibilidad antibiótica del género Salmonella en Elche. Rev. Esp. Quimioter. 15:2002;55-60
11. Cruchaga S., Echeita A., Aladueña A., Garcia-peña J., Frias N., Usera M.A. Antimicrobial resistance in salmonellae from humans, food and animals in Spain in 1998. J. Antimicrob. Chemother. 47:2001;315-321
12. Molbak K., Gerner-Smidt P., Wegenwe H.C. Increasing quinolone resistance in Salmonella enterica serotype Enteritidis. Emerg. Infect. Dis. 8:2002;514-515
13. Threlfall E.J., Ward L.R., Rowe B. Resistance to ciprofloxacin in non-typhoidal salmonellas from humans in England and Wales - the current situation. Clin. Microbiol. Infect. 5:1999;130-134
14. Threlfall E.J., Ward L.R., Skinner J.A., Graham A. Antimicrobial drug resistance in non-typhoidal salmonellas from humans in England and Wales in 1999: decrease in multiple resistance in Salmonella enterica serotypes Typhimurium, Virchow, and Hadar. Microb. Drug Resist. 6:2000;319-325
15. Hakanen A., Siitonen A., Kotilainen P., Huovinen P. Increasing fluoroquinolone resistance in salmonella serotypes in Finland during 1995-1997. J. Antimicrob. Chemother. 43:1999;145-148
16. Frost J.A., Kelleher A., Rowe B. Increasing ciproloxacin resistance in salmonellas in England and Wales 1991-1994. J. Antimicrob. Chemother. 37:1996;85-91
17. Threlfall E.J., Graham A., Cheasty T., Ward L.R., Rowe B. Resistance to ciprofloxacin in pathogenic Enterobacteriaceae in England and Wales in 1996. J. Clin. Pathol. 50:1997;1027-1028
18. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility test for bacterial that grow aerobically. Approved Standard M7-A5. NCCLS, Wayne, PA, 2000.
19. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing: tenth informational supplement (aerobic dilution) M100-S10 (M7). NCCLS, Wayne, PA, 2000.
20. Mesa Española de Normalización de la Sensibilidad y Resistencia a los Antimicrobianos (MENSURA). Recomendaciones del grupo MENSURA para la selección de antimicrobianos en el estudio de la sensibilidad y criterios para la interpretación del antibiograma. Rev Esp Quimioter 2000;13:73-6.
21. Giraud E., Brisabois A., Martel J.L., Chaslus-Dancla E. Comparative studies of mutations in animal isolates and experimental in vitro- and in vivo-selected mutants of Salmonella spp. suggest a counterselection of highly fluoroquinolone-resistant strains in the field. Antimicrob. Agents Chemother. 43:1999;2131-2137
22. Griggs D.J., Gensberg K., Piddock L.J.V. Mutations in gyrA gene of Quinolone-resistant Salmonella serotypes isolated from humans and animals. Antimicrob. Agents Chemother. 40:1996;1009-1013
23. Hakanen A., Kotilainen P., Huovinen P., Helenius P., Siitonen A. Reduced fluoroquinolone susceptibility in Salmonella enterica serotypes in travellers returning from southeast Asia. Emerg. Infect Dis. 7:2001;996-1003
24. Walker R.A., Saunders N., Lawson A.J., et al. Use of a LightCycler gyrA mutation Assay for rapid identification of mutations conferring decreased susceptibility to ciprofloxacin in multiresistant Salmonella enterica serotype Typhimurium DT104 isolates. J. Clin. Microbiol. 39:2001;1443-1448
25. Piddock L.J.V., Ricci V., McLaren I., Griggs D.J. Role of mutations in the gyrA and parC genes of nalidixic-acid-resistant Salmonellaserotypes isolated from animals in the United Kingdom. J. Antimicrob. Chemother. 41:1998;635-641
26. Piddock L.J.V. Fluoroquinolone resistance in Salmonella serovars isolated from humans and food animals. FEMS Microbiol. Rev. 26:2002;3-16
27. Ruíz J., Castro D., Goni P., Santamaria J.A., Borrego J.J., Vila J. Analysis of the mechanism of quinolone resistance in nalidixic acid-resistant clinical isolates of Salmonella serotype Typhimurium. J. Med. Microbiol. 46:1997;623-628
28. Wain J., Hoa N.T., Chinh N.T., et al. Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin. Infect. Dis. 25:1997;1404-1410
29. Molbak K., Baggesen D.L., Aarestrup F.M., et al. An outbreak of multidrug-resistant, quinolone-resistant Salmonella enterica serotype Typhimurium DT104. N. Engl. J. Med. 341:1999;1420-1425
30. Brown J.C., Thomson C.J., Amyes S.G. Mutations of the gyrA gene of clinical isolates of Salmonella typhimurium and three other Salmonella species leading to decreased susceptibilities to 4-quinolone drugs. J. Antimicrob. Chemother. 37:1996;351-356
31. Piddock L.J.V. Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992-1994. Drugs. 49(Suppl. 2):1995;29-35
32. Martinez J.L., Alonso A., Gomez-Gomez J.M., Baquero F. Quinolone resistance by mutations in chromosomal gyrase genes. Just the tip of the iceberg? J. Antimicrob. Chemother. 42:1998;683-688
33. Crump J.A., Barrett T.J., Nelson J.T., Angulo F.J. Revaluating fluoroquinolone breakpoints for Salmonella enterica serotype. Typhi and for non-Typhi salmonellae. Clin. Infect. Dis. 37:2003;75-81
34. Aarestrup F.M., Wiuff C., Molbak K., Threlfall E.J. Is it time to change fluoroquinolone breakpoints for Salmonella spp.? Antimicrob. Agents Chemother. 47:2003;827-829